CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

CareDx (CDNA) reported robust Q3 2025 financial results, with total revenue increasing 21% year-over-year to $100.1 million and adjusted EBITDA more than doubling to $15.3 million, prompting a raised full-year 2025 revenue guidance to $372-$376 million and adjusted EBITDA to $35-$39 million. This strong performance was attributed to record volumes across all business segments and significant improvements in revenue cycle management, which accelerated cash collections and reduced Days Sales Outstanding. Operational efficiencies, including successful EPIC Aura integrations, and product innovation, such as the upcoming HistoMap Kidney launch and new clinical evidence for its HeartCare solution, are key drivers, while the company continues to monitor the finalization of the draft LCD policy for molecular testing.

Analysis

CareDx (CDNA) reported a strong third quarter in 2025, with total revenue increasing 21% year-over-year to $100.1 million and adjusted EBITDA more than doubling to $15.3 million. This robust performance, driven by record volumes across testing services, patient and digital solutions, and lab products, led the company to raise its full-year 2025 revenue guidance to $372-$376 million and adjusted EBITDA guidance to $35-$39 million.

Operational efficiencies significantly contributed to these results, with Revenue Cycle Management (RCM) improvements leading to 124% cash collections relative to testing services revenue, a $19 million reduction in accounts receivable, and a 38% improvement in Days Sales Outstanding. The successful EPIC Aura integration at Boston Children's demonstrated a 20% reduction in order turnaround time and a 60% reduction in specimen holds, with 10% of total volume expected through EPIC by year-end 2025.

Product innovation remains a key driver, highlighted by the upcoming launch of HistoMap Kidney in early 2026, a tissue-based molecular test for precise rejection subtyping. Furthermore, new SHORE registry data validated HeartCare (AlloMap and AlloSure Heart) as a highly specific non-invasive approach for diagnosing antibody-mediated rejection in heart transplantation, reinforcing its clinical utility.

While the company repurchased an additional 2 million shares in Q3, bringing the year-to-date total to 9% of shares outstanding, the macro environment shows flat overall transplant volumes, partly due to media attention around the IOTA program. CareDx anticipates the draft LCD policy to finalize in early 2026, projecting a $15 million reimbursement headwind but no change in clinician utilization behavior.

Key Decisions for Investors

• Monitor the finalization of the draft LCD policy in early 2026 for potential impacts on reimbursement and long-term average revenue per test, despite management's current outlook on utilization.
• Evaluate the sustained effectiveness and scalability of CareDx's RCM improvements and EPIC Aura integrations, as these operational efficiencies are critical for continued margin expansion and predictable cash flow.
• Assess the market adoption and revenue contribution of new products like HistoMap Kidney and the ongoing growth of HeartCare, particularly in the context of flat overall transplant volumes and competitive dynamics.